開曼群島 公司法（經修訂） 股份有限公司 微創醫療科學有限公司 之 經第五次修訂及重訂的組織章程大綱及細則 （經於二零二五年十月二十二日通過的特別決議案採納） – 1 – 開曼群島 公司法（經修訂） 股份有限公司 微創醫療科學有限公司 之 經第五次修訂及重訂的組織章程大綱 公司法（經修訂） 股份有限公司 微創醫療科學有限公司 之 經第五次修訂及重訂的組織章程大綱 （經於二零二五年十月二十二日通過的特別決議案採納） – 3 – 1 本公司的名稱為微創醫療科學有限公司。 2 本公司的註冊辦事處設於PO Box 309, Ugland House, Grand Cayman, KY1-1104, Cayman Islands, Maples Corporate Services Limited的辦事處，或董事會不時決定的其 他地點。 3 本公司的成立宗旨並無限制，包括但不限於以下各項： (a) 以投資公司及投資控股公司的形式經營業務，以及收購及持有由任何性質及在任 何地點成立或經營業務的任何公司、企業或實體發行或擔保的任何種類的股份、 股票、債權股份、債券、按揭、債務及證券、由任何政府、主權執政者、專責 機構、信託 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性或完 整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容而產生或因倚賴該等內 容而引致的任何損失承擔任何責任。 1 附註： 承董事會命 微創醫療科學有限公司* 主席 微創醫療科學有限公司* （於開曼群島註冊成立的有限公司） （股份代號：00853) 於二零二五年十月二十二日舉行之股東特別大會的表決結果 微創醫療科學有限公司（「本公司」）之董事會（分別為「董事」及「董事會」）欣然公佈，刊載於日期為二零 二五年九月三十日之本公司股東特別大會（「股東特別大會」）通告內的提呈決議案，已於二零二五年 十月二十二日舉行之股東特別大會上，以按股數投票表決方式獲本公司普通股之持有人（分別為「股 份」及「股東」）正式通過。投票表決結果如下： | | 特別決議案 | 票數(%) | | | --- | --- | --- | --- | | | | 贊成 | 反對 | | 1. | 「動議批准及採納經第五次修訂及重訂的本公司組織 | 473,216,694 | 0 | | | 章程大綱及組織章程細則（「新章程細則」）（其副本已 | ...

Group 1 - The core point of the news is that southbound funds have significantly increased their holdings in MicroPort Scientific Corporation (00853.HK), with a total net increase of 13.18 million shares over the last five trading days and 47.15 million shares over the last twenty trading days [1][2] - As of October 17, 2025, southbound funds hold 876 million shares of MicroPort, accounting for 45.8% of the company's total issued ordinary shares [1][2] - The daily changes in shareholding show fluctuations, with a notable increase of 4.95 million shares on October 16, 2025, and a decrease of 519,300 shares on October 15, 2025 [2] Group 2 - MicroPort Scientific Corporation specializes in the manufacturing and sales of medical devices, with divisions focused on orthopedic, cardiovascular, neuro-interventional, surgical, robotic, cardiac rhythm management, and heart valve products [2]

Core Insights - The top three companies with the highest short positions as of October 3 are COSCO Shipping Holdings (01919), Ganfeng Lithium (01772), and ZTE Corporation (00763), with short ratios of 15.66%, 15.25%, and 15.16% respectively [1][2] - Ganfeng Lithium (01772) saw the largest absolute increase in short positions, rising by 1.20%, followed by Minmetals Resources (01208) with an increase of 0.96%, and Yuexiu Transport Infrastructure (01052) with an increase of 0.76% [1][2] - The companies with the largest decreases in short positions include GCL-Poly Energy (03800), which decreased by 3.16%, followed by Dongfang Electric (01072) with a decrease of 2.03%, and Jinxin Fertility (01951) with a decrease of 0.76% [1][3] Summary of Short Positions - **Top 10 Companies by Short Ratio** - COSCO Shipping Holdings (01919): 15.66% (from 437 million shares to 451 million shares) - Ganfeng Lithium (01772): 15.25% (from 62.30 million shares to 67.64 million shares) - ZTE Corporation (00763): 15.16% (from 113 million shares to 115 million shares) - CATL (03750): 13.83% (from 21.12 million shares to 21.57 million shares) - Vanke (02202): 12.63% (from 268 million shares to 279 million shares) - Ping An Insurance (02318): 12.59% (from 959 million shares to 938 million shares) - Zijin Mining (02899): 12.58% (from 750 million shares to 754 million shares) - MicroPort Medical (00853): 11.10% (from 213 million shares to 212 million shares) - Hansoh Pharmaceutical (01276): 11.01% (from 28.01 million shares to 28.43 million shares) - Fuyao Glass (06865): 10.85% (from 49.22 million shares to 47.94 million shares) [2] - **Top 10 Companies with Increased Short Positions** - Ganfeng Lithium (01772): Increased by 1.20% (from 14.05% to 15.25%) - Minmetals Resources (01208): Increased by 0.96% (from 1.96% to 2.93%) - Yuexiu Transport Infrastructure (01052): Increased by 0.76% (from 1.08% to 1.84%) - Jinli Permanent Magnet (06680): Increased by 0.66% (from 7.76% to 8.42%) - China Civil Aviation Information Network (00696): Increased by 0.58% (from 6.63% to 7.21%) [2] - **Top 10 Companies with Decreased Short Positions** - GCL-Poly Energy (03800): Decreased by 3.16% (from 11.76% to 8.59%) - Dongfang Electric (01072): Decreased by 2.03% (from 6.78% to 4.75%) - Jinxin Fertility (01951): Decreased by 0.76% (from 10.61% to 9.85%) - Yangtze Optical Fibre and Cable (06869): Decreased by 0.75% (from 7.03% to 6.28%) - Shanghai Electric (02727): Decreased by 0.72% (from 2.25% to 1.52%) [3][4]

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年9月30日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 微創醫療科學有限公司 呈交日期: 2025年10月8日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 00853 | 說明 | | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 5,000,000,000 | USD | | 0.00001 | USD | | 50,000 | | 增加 / 減少 (-) | | | | | | | USD | | | | 本月底結存 | | | 5,000,000,000 | USD | | 0.00001 | USD | | 50,000 | 本月底法定/註冊股本總 ...

Core Viewpoint - MicroPort Medical (00853) has seen a significant increase in stock price, rising 5.1% to HKD 16.08, with a trading volume of HKD 267 million, following the announcement of a restructuring in its cardiac rhythm management business [1] Group 1: Business Restructuring - MicroPort Medical announced the restructuring of its cardiac rhythm management business, with its subsidiary MicroPort Cardiac Rhythm Management planning to merge with CRM Cayman [1] - Market analysts suggest that this merger aims to alleviate the pressure of meeting listing standards for the cardiac rhythm business [1] - JPMorgan indicated that the successful completion of this transaction would help eliminate significant uncertainties that have been troubling the company [1] Group 2: Strategic Partnerships - The company previously introduced Shanghai Industrial, a state-owned enterprise, as a strategic shareholder [1] - According to Guotai Junan Securities, Shanghai Industrial's capital, backed by its state-owned background and industrial resources, is expected to support the group's core business expansion and potential strategic acquisitions [1] - This partnership aims to enhance corporate governance and facilitate continuous innovation, high-quality development, and scale improvement for the group [1]

Core Viewpoint - MicroPort Medical (00853) has seen a 5.1% increase in stock price, reaching HKD 16.08, with a trading volume of HKD 267 million, following the announcement of a restructuring in its cardiac rhythm management business [1] Group 1: Business Restructuring - MicroPort Medical announced the merger of its subsidiary, MicroPort Cardiac Rhythm Management (CRM) Cayman, as part of a restructuring effort [1] - The merger aims to alleviate the pressure of meeting the "listing performance" targets associated with the cardiac rhythm business [1] Group 2: Market Reactions - Market analysts, including those from JPMorgan, indicated that the successful completion of the transaction would help eliminate significant uncertainties that have been troubling the company [1] - The introduction of Shanghai Industrial Holdings as a strategic shareholder is expected to enhance the company's core business expansion and potential strategic acquisitions [1] Group 3: Strategic Support - The state-owned background of Shanghai Industrial is anticipated to provide valuable industry resources and support for the company's governance and innovation efforts [1] - The partnership is expected to facilitate high-quality development and scale enhancement for the group [1]

Core Viewpoint - MicroPort Medical (00853) has seen a nearly 5% increase in stock price, currently trading at 15 HKD, with a transaction volume of 86.87 million HKD, following the announcement of a restructuring in its cardiac rhythm management business [1] Group 1: Business Restructuring - MicroPort Medical announced the merger of its subsidiary MicroPort Cardiac Rhythm Management (CRM) with CRM Cayman, which will become a wholly-owned subsidiary post-merger [1] - The merger aims to alleviate the pressure of meeting the "listing target" for the cardiac rhythm business, as noted by market analysts [1] Group 2: Market Reactions and Analyst Insights - JPMorgan expressed that the successful completion of the transaction would help eliminate significant uncertainties that have been troubling the company [1] - Bank of America Securities highlighted the strategic partnership with Shanghai Industrial, a state-owned enterprise, which is expected to support the company's financial and business development [1] Group 3: Future Profitability and Growth - The bank anticipates that through cost control and the disposal of non-core assets, the company could achieve profitability by the first half of 2026 [1] - Rapid growth in overseas business is expected to diversify domestic market risks and provide long-term growth visibility [1]

Core Viewpoint - MicroPort Medical (00853) has seen a nearly 5% increase in stock price, currently trading at 15 HKD, with a transaction volume of 86.87 million HKD. The company announced a restructuring of its cardiac rhythm management business, which is expected to alleviate pressure related to the "listing performance" gamble [1]. Group 1: Business Restructuring - MicroPort Medical's subsidiary, MicroPort Cardiac Rhythm Management (CRM), plans to merge with CRM Cayman, which will become a wholly-owned subsidiary post-merger [1]. - The merger is aimed at resolving uncertainties that have been a significant concern for the company [1]. Group 2: Market Analysis - JPMorgan has indicated that the successful completion of the transaction will help eliminate major uncertainties that have been affecting the company [1]. - Bank of America Securities has noted that the introduction of a state-owned enterprise, Shanghai Industrial, as a strategic shareholder will support the company's financial and business development [1]. Group 3: Financial Outlook - The bank anticipates that through cost control and the disposal of non-core assets, the company could achieve profitability by the first half of 2026 [1]. - Rapid growth in overseas business is expected to diversify domestic market risks and provide long-term growth visibility [1].

Core Viewpoint - MicroPort Medical (00853) is restructuring its cardiac rhythm management business, which is expected to enhance operational clarity and support future growth [1] Group 1: Business Restructuring - MicroPort Medical announced the merger of its subsidiary MicroPort Cardiac Rhythm Management (CRM) with CRM Cayman, which will become a wholly-owned subsidiary focused on arrhythmia management solutions [1] - The pre-transaction equity value of CRM Cayman is estimated at $680 million [1] Group 2: Shareholding and Strategic Partnerships - MicroPort Medical currently holds a 46.12% stake in MicroPort Cardiac Rhythm Management and a 50.13% stake in CRM Cayman [1] - The introduction of Shanghai Industrial Holdings as a strategic shareholder is expected to support the company's financial and business development [1] Group 3: Financial Outlook - Analysts from JPMorgan believe that the merger will eliminate significant uncertainties that have been affecting the company [1] - Bank of America Securities anticipates that through cost control and divestment of non-core assets, the company could achieve profitability by the first half of 2026 [1] - Rapid growth in overseas business is expected to mitigate domestic market risks and provide long-term growth visibility [1]